TY - JOUR
T1 - Disparities in the Treatment and Outcome of Stage I Non–Small-Cell Lung Cancer in the 21st Century
AU - Dalwadi, Shraddha M.
AU - Lewis, Gary D.
AU - Bernicker, Eric H.
AU - Butler, Edward Brian
AU - Teh, Bin S.
AU - Farach, Andrew M.
N1 - Copyright © 2018 Elsevier Inc. All rights reserved.
PY - 2019/5
Y1 - 2019/5
N2 - BACKGROUND: African American (AA) individuals are less likely to receive treatment and more likely to die from cancer compared with Caucasian (C) individuals. Recent advancements in surgery and radiation have improved outcomes in early stage non-small-cell lung cancer (ESNSCLC). We studied racial disparities in ESNSCLC in the past decade.PATIENTS AND METHODS: The Surveillance, Epidemiology, and End Results database was used to retrieve data of 62,312 ESNSCLC patients age 60 years and older diagnosed between 2004 and 2012. Patients were divided into racial cohorts: C, AA, American Indian (AI), Asian/Pacific Islander (API), or unknown. Demographics characteristics, therapy, and survival were compared using χ
2 test, Kaplan-Meier method, and Cox multivariate analysis.
RESULTS: AA and AI individuals were less likely to receive surgery than typical ESNSCLC patients (55.9% and 57.6% vs. 66.7%; P < .0001). Two-year overall survival (OS) for C individuals was 70%, for AA 65%, AI 60%, and API 76% (P < .0001). Two-year cancer-specific survival (CSS) for C individuals was 79%, AA 76%, AI 73%, and API 84% (P < .0001). Median CSS for AI and AA individuals was less than that of typical ESNSCLC patients (49 and 80 months vs. 107 months; P < .0001). This difference disappeared in multivariate analysis, accounted by sex, age, treatment, histology, and T stage (all P < .0001).CONCLUSION: Despite treatment advancements in the past decade, AA and AI individuals continue to have worse OS and CSS from ESNSCLC. This might be because of the association with more adverse risk factors, including older age, squamous histology, male sex, T2 stage, and tendency to forgo treatment.
AB - BACKGROUND: African American (AA) individuals are less likely to receive treatment and more likely to die from cancer compared with Caucasian (C) individuals. Recent advancements in surgery and radiation have improved outcomes in early stage non-small-cell lung cancer (ESNSCLC). We studied racial disparities in ESNSCLC in the past decade.PATIENTS AND METHODS: The Surveillance, Epidemiology, and End Results database was used to retrieve data of 62,312 ESNSCLC patients age 60 years and older diagnosed between 2004 and 2012. Patients were divided into racial cohorts: C, AA, American Indian (AI), Asian/Pacific Islander (API), or unknown. Demographics characteristics, therapy, and survival were compared using χ
2 test, Kaplan-Meier method, and Cox multivariate analysis.
RESULTS: AA and AI individuals were less likely to receive surgery than typical ESNSCLC patients (55.9% and 57.6% vs. 66.7%; P < .0001). Two-year overall survival (OS) for C individuals was 70%, for AA 65%, AI 60%, and API 76% (P < .0001). Two-year cancer-specific survival (CSS) for C individuals was 79%, AA 76%, AI 73%, and API 84% (P < .0001). Median CSS for AI and AA individuals was less than that of typical ESNSCLC patients (49 and 80 months vs. 107 months; P < .0001). This difference disappeared in multivariate analysis, accounted by sex, age, treatment, histology, and T stage (all P < .0001).CONCLUSION: Despite treatment advancements in the past decade, AA and AI individuals continue to have worse OS and CSS from ESNSCLC. This might be because of the association with more adverse risk factors, including older age, squamous histology, male sex, T2 stage, and tendency to forgo treatment.
KW - Access
KW - Race
KW - SBRT
KW - SEER
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85059871566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059871566&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2018.11.004
DO - 10.1016/j.cllc.2018.11.004
M3 - Article
C2 - 30655194
AN - SCOPUS:85059871566
SN - 1525-7304
VL - 20
SP - 194
EP - 200
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 3
ER -